Choate represented CytoTronics in the transaction. CytoTronics, a biotechnology company building a next-generation complementary metal-oxide-semiconductor (CMOS)-powered drug discovery platform, closed its $9.25 million initial seed funding,...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here